Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Mat D. Davis"'
Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease
Autor:
Mark Forrest Gordon, David Oakes, Elise Kayson, Juha-Matti Savola, Nicholas Gross, Mat D. Davis, Jacquelyn Whaley, Maria Wieman, Samuel Frank, Claudia M. Testa, Shirley Eberly, Christina Vaughan, Jody Goldstein, David Stamler
Publikováno v:
CNS Spectrums. 26:162-163
BackgroundIn the First-HD pivotal trial, the maximum deutetrabenazine dose evaluated to treat chorea associated with Huntington’s disease (HD chorea) was 48 mg/d, which is the approved maximum dose for this population. In ARC-HD, an open-label exte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::153786e18f6d851621dcebf5e0f11539
https://doi.org/10.1017/s1092852920002618
https://doi.org/10.1017/s1092852920002618
Autor:
David Oakes, Samuel Frank, Jody Goldstein, Mat D. Davis, David Stamler, Christina Vaughan, Jacquelyn Whaley, Claudia M. Testa, Mark Forrest Gordon, Elise Kayson, Juha-Matti Savola
Publikováno v:
CNS Spectrums. 26:164-165
BackgroundChorea is a prominent motor dysfunction in Huntington’s disease (HD). Deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, is FDA-approved for the treatment of chorea in HD. In the pivotal, 12-week First-HD trial, deut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07132bae31fd5e85591b2f95501346b4
https://doi.org/10.1017/s1092852920002655
https://doi.org/10.1017/s1092852920002655
Autor:
Peter, Rieckmann, Robert, Zivadinov, Alexey, Boyko, Krzysztof, Selmaj, Jessica K, Alexander, Shaul, Kadosh, Svetlana, Rubinchick, Emily, Bernstein-Hanlon, Yafit, Stark, Natalia, Ashtamker, Mat D, Davis, Omar, Khan
Publikováno v:
Multiple Sclerosis Journal-Experimental, Translational and Clinical
Objective Describe the long-term outcomes of early-start (ES) and delayed-start (DS) glatiramer acetate 40 mg/mL treatment three times weekly (GA40) for up to seven years in the Glatiramer Acetate Low-frequency Administration (GALA) study in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5688c0832e1828f3dbeed8988343c497
https://doi.org/10.1177/20552173211061550
https://doi.org/10.1177/20552173211061550
Autor:
L. Fredrik Jarskog, Joohi Jimenez-Shahed, Mat D. Davis, William G. Ondo, David Stamler, Jouko Isojärvi, Rajeev Kumar, Stanislaw Ochudlo, Stewart A. Factor, Hubert H. Fernandez, Karen E. Anderson, Robert A. Hauser, Joseph P. McEvoy
Publikováno v:
The Lancet Psychiatry. 4:595-604
Summary Background Tardive dyskinesia results from exposure to dopamine receptor antagonists, such as typical and atypical antipsychotics. If clinically appropriate, clinicians often manage this disorder by lowering the dose of, or discontinuing, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2b593204622164a40de73744e3d1164
https://doi.org/10.1016/s2215-0366(17)30236-5
https://doi.org/10.1016/s2215-0366(17)30236-5
Autor:
Herbert Y. Meltzer, Joohi Jimenez-Shahed, William G. Ondo, David Stamler, L. Fredrik Jarskog, David Shprecher, Hubert H. Fernandez, Charles S. Davis, Robert A. Hauser, Scott W. Woods, Stewart A. Factor, Karen E. Anderson, Danny Bega, Mark S. LeDoux, Mat D. Davis
Publikováno v:
Neurology
Objective:To determine the efficacy and safety of deutetrabenazine as a treatment for tardive dyskinesia (TD).Methods:One hundred seventeen patients with moderate to severe TD received deutetrabenazine or placebo in this randomized, double-blind, mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebc80e46644da803f6823aa56ad4cc95
https://doi.org/10.1212/wnl.0000000000003960
https://doi.org/10.1212/wnl.0000000000003960
Autor:
Omar Khan, Robert Zivadinov, Alexey Boyko, Peter Rieckmann, Krzysztof Selmaj, Scott Kolodny, Natalia Ashtamker, Mat D. Davis
Publikováno v:
Multiple Sclerosis Journal. 23:818-829
Background: The 1-year placebo-controlled (PC) phase of the Glatiramer Acetate Low-Frequency Administration (GALA) study showed that glatiramer acetate 40 mg/mL three times weekly (GA40) significantly reduced annualized relapse rate (ARR) and magneti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9230c2587c03bc1ee6d089d5978a6416
https://doi.org/10.1177/1352458516664033
https://doi.org/10.1177/1352458516664033
Autor:
Scott W. Woods, Joohi Jimenez-Shahed, Stewart A. Factor, Hubert H. Fernandez, David Shprecher, L. Fredrik Jarskog, David Stamler, Karen E. Anderson, Mat D. Davis, Robert A. Hauser, William G. Ondo, Danny Bega, Mark S. LeDoux
Publikováno v:
Journal of Neurology, Neurosurgery, and Psychiatry
ObjectiveTo evaluate the long-term safety and efficacy of deutetrabenazine in patients with tardive dyskinesia (TD).MethodPatients with TD who completed the 12 week, phase 3, placebo-controlled trials were eligible to enter this open-label, single-ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::300b10644afb4d85cf6640a03aab4102
https://pubmed.ncbi.nlm.nih.gov/31296586
https://pubmed.ncbi.nlm.nih.gov/31296586
Autor:
Mat D. Davis, David Stamler, Robert A. Hauser, L. Fredrik Jarskog, Joseph P. McEvoy, Hubert H. Fernandez, Stanislaw Ochudlo, Rajeev Kumar, Joohi Jimenez-Shahed, Nicholas Gross, Karen E. Anderson
Publikováno v:
CNS Spectrums. 24:193-194
BackgroundTardive dyskinesia (TD) is an often-irreversible movement disorder that may intensify the stigma of patients with psychiatric disorders and worsen quality of life. In two randomized, double-blind, placebo (PBO)-controlled, 12-week trials, A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d47ea500568392eded991fb013dea74
https://doi.org/10.1017/s1092852919000294
https://doi.org/10.1017/s1092852919000294
Autor:
Scott W. Woods, David Stamler, Karen E. Anderson, Hubert H. Fernandez, L. Fredrik Jarskog, William G. Ondo, Mat D. Davis, Joohi Jimenez-Shahed, Stewart A. Factor, Robert A. Hauser, David Shprecher, Mark S. LeDoux
Publikováno v:
CNS Spectrums. 24:200-201
Study ObjectiveTo evaluate long-term efficacy of deutetrabenazine in patients with tardive dyskinesia (TD) by examining response rates from baseline in Abnormal Involuntary Movement Scale (AIMS) scores. Preliminary results of the responder analysis a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44dbc00bb812fc55349e86fbd409d464
https://doi.org/10.1017/s1092852919000385
https://doi.org/10.1017/s1092852919000385
Autor:
Michael R. Hayden, Brian Weiner, Volker Knappertz, Iris Grossman, Rebecca Kusko, Colin J. D. Ross, Fadi Towfic, Mathis Thoma, Jyoti Shankar, Mat D. Davis, Daphna Laifenfeld, Ben Zeskind
Publikováno v:
Genome Medicine
Genome Medicine, Vol 9, Iss 1, Pp 1-15 (2017)
Genome Medicine, Vol 9, Iss 1, Pp 1-15 (2017)
Background Copaxone is an efficacious and safe therapy that has demonstrated clinical benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On an individual level, patients show variability in their response to Cop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cd998a1c0ce0bd10306ace2cf390659
https://doi.org/10.1186/s13073-017-0436-y
https://doi.org/10.1186/s13073-017-0436-y